Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine

Pediatric Hematology and Oncology

Volumn 13, Issue 5, 1996, Pages 425-431

  Polychronopoulou Androulakaki, Sophia ^a,c   Panagiotou, John P ^a   Kostaridou, Stavroula ^b   Kyratzopoulou, Asimina ^a   Haidas, Stavros ^a  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

childhood; HBV vaccination; Immune response; malignancies

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD TRANSFUSION REACTION; CANCER REGRESSION; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HEPATITIS B; HUMAN; IMMUNE DEFICIENCY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; VACCINATION;

EID: 0029794727     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019609030854     Document Type: Article

References (25)

1. Devine P, Postoway N, Hoffstadter L, et al. Blood donation and transfusion practices: The 1990 American Association of Blood Banks Institutional Membership Questionnaire. Transfusion. 1992;32:683-687
2. Tabor E, Gerety KJ, Mott M, et al. Prevalence of hepatitis B in a high risk setting: A serologic study of patients and staff in a Paediatric Oncology Unit, Paediatrics. 1978;61:711-715.
3. Locasciulli A, Gornati G, Tagger A, et al. Hepatitis C virus infection and chronic liver disease in children with leukemia in long term remission. Blood. 1991;78:1619-1622.
4. Nagington J, Cossart YE, Cohen BJ. Reactivation of hepatitis B after transplantation operations. Lancet. 1977;1:558-560.
5. Locasciulli A, Mieli Vergani G, Underzo D, et al. Evidence of non-A, non-B hepatitis in children with acute leukemia and chronic liver disease. Am J Dis Child 1983;173:354-356.
6. Sobeslavsky O. Prevalence of markers of hepatitis B virus infection in various countries: A WHO collaborative study. Bull WHO. 1980;58(4):621-628.
7. Tassopoulos NC, Papatheodoridis GV. Epidemiology of hepatitis B virus infection. Hellenic J Gastroenterol. 1993;6:67-73.
8. Kattamis C. Epidemiology and immunoprophylaxis in viral hepatitis. Paediatriki. 1993;56:25-37.
9. WHO Wkly Epidem Rec. 1989;64:289-290.
10. Maynard JE. Hepatitis B: Global importance and need for control. Vaccine. 1990;8(suppl):S18-S20.
11. Papaevangelou D, Roumeliotou-Karayanis A, Tassopoulos NC, et al. Evaluation of methods of Papaevangelou pre-vaccination screening for markers of hepatitis B infection. Eur J Epidemiol. 1985;1:100-103.
12. Maynard JE, Kane MA, Alter MJ, Hadler SC. Control of hepatitis B by immunization: Global perspectives. In: Viral Hepatitis and Liver Disease. New York: Alan R. Liss, 1988:967-969.
13. Beasley RP. Hepatitis B virus - The major etiology of hepatocellular carcinoma. Cancer. 1988; 61:1642-1656.
14. Brechot C. Hepatitis B virus (HBV) and hepatocellular carcinoma. J Hepatol. 1987;4:269-279.
15. Ridgway D, Wolff LJ. Active immunization of children with leukemia and other malignancies. Leuk Lymphoma 1993;9:177-192
16. Pauksen K, Duraj V, Ljungman P, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant. 1992;9:427-432.
17. Trappaz D, Bonnevial L, Bouteille M, et al. Vaccination contre l'hépatite B chez l'enfant immunodéprimé. A propos de 31 cas personnels. Pediatrie. 1986;4:537-548.
18. Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 1990;8(suppl):S74-S78.
19. Scheiermann N, Gesemann M, Maurer C, et al. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine 1990;8:(suppl):S44-S46.
20. Mok Q, Underhill G, Wonke B, et al. Intradermal hepatitis B vaccine in thalassaemia and sickle cell disease. Arch Dis Child. 1989;64:535-540.
21. Cimaglia A, Villani S, Buonagura G, et al. Epatite B in pediatria. Considerazioni sulla vaccinazione in corso di leucemia. Pediatr Med Chir. 1986;8:547-549.
22. Entacher U, Jurgenssen O, Thus-Hohenstein L, et al. Hepatitis B vaccination and immune response in children with malignant diseases. Eur J Pediatr. 1985;144:160-163.
23. Carne CA, Weller IVD. Waite J, et al. Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. Br Med J. 1987;294:866-868.
24. Rosen HR, Stierer M, Wolf HM, et al. Impaired primary antibody responses after vaccination against hepatitis B in patients with breast cancer. Breast Cancer Res Treat. 1992;23:233-240.
25. Meuer SC, Dumann H, Meyer zum Buschenfelde KH. Low dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989;1:15-18.